CVM: CEL-SCI Corp (H1N1 play)

[marketwatch]

I half hazardly without proper DD picked this up late on Friday and had a gain of almost 20% today. Honestly I was expected a pump and dump but every time it drop from 19%+ to 16%+ it stopped going down and recovered, this happened throughout the day.

Article from today probably helped push this stock along...

CEL-SCI's Postive Perfect Storm


[Link Removed]

Any thoughts about this stock?

[stockman]

CVM is headed back to the 1.70's

[Lucifer]

A lot of hype right now with the flu shot season upon us
CVM is benefitting from all the hype but I don't think they have what it takes to back it up in the short term
It would be a pumpNdump play at best in the mean time
Good luck to all

[stockman]

With this type exposure CVM will run today: it's already 1.64 in the pm

Cel Sci's (AMEX:CVM) Multikine®. Multikine® is a head and neck cancer immunotherapy treatment that has been on the sidelines for some time awaiting the commencement of a Phase III trial which Cel Sci has recently stated may begin later this year. Multikine, in my opinion, could be huge if Phase III trials offer the same positive results as the Phase II trials did. In a couple of weeks, the company is expected to unveil it's new state-of-the-art manufacturing facility, where it expects to manufacture Multikine® for that pivotal Phase III trial, will be used for the process known as cold 4°C Aseptic Filling on a contract basis to stem cell and biologic companies, academic institutions and commercial media suppliers.

As a short term play, CEL-SCI's shares also look attractive and have been rising steadily in recent weeks due to their FDA fast-tracked H1N1 (Swine Flu) treatment based on the company's proprietary L.E.A.P.S. technology. There are newly published reports indicating that CEL-SCI could be granted an Emergency Use Approval of their investigational LEAPS-H1N1 treatment for patients hospitalized due to exposure and infection of H1N1 since no other form of treatment exists for such patients. In similar fashion, since the beginning of September, shares of Cepheid (NASDAQ:CPHD) have been rising sharply in anticipation of the very same type emergency FDA approval for their Flu A (Influenza Virus) Panel. The company announced in early September that the test was under EUA review by the FDA for use during the upcoming influenza season, with product shipments beginning in January 2010. A Cepheid official said yesterday that the firm expects to receive that Emergency Use Authorization and that the firm expects to file for full FDA clearance of the test after it receives the EUA. The test helps identify H1, H3, and novel H1N1 strains and will provide results in 45 minutes. Healthcare providers and patients all over the country have been requesting that such a test be made available as soon as possible given it's urgent need in the face of the growing pandemic. The L.E.A.P.S. platform was also mentioned yesterday on Bloomberg Television during a segment about some of the issues facing biotech companies during the upcoming H1N1 flu season.
Getting back to the subject at hand, it has long been my opinion that we are on the verge of something big in the arena of cancer treatment and I believe that the cancer vaccines are the next big thing. Patients and Doctors have been lobbying for years for these treatments to become available and it looks like we are getting close to the time that there wishes will be granted.

And yet the full potential of these vaccines is still untapped, in my opinion. They have only been tested on patients that are also receiving chemotherapy and/or radiation treatments, which wreak havoc on a body's immune system. If a cancer vaccine had a healthy immune system to work with - one that was not already beat down by time and other treatments - you have to wonder just how much more of a benefit the treatment would provide to the patient.

When Dendreon announced their plans for the future of Provenge, it offered an insight into what could be coming next for cancer patients, Doctors and investors of the sector. With the potential of the cancer immunotherapy treatments now coming to light, we're looking at a scenario where everybody wins - patients and investors alike.

I always like to point out, however, that the patients bear the true benefit of these treatments - life; an investor's financial gains are largely secondary and hugely unimportant by comparison.


CVM on bloomberg yesterday heres the youtube link


YouTube - In-Depth Look - HIV Vaccine Shows Promise

[stockman]

And she's off

[karmakazi]

Found this article on CVM from a couple days ago, seems quite promising:

"This stock is still way undervalued but no stock in the history of the world has ever gone straight up forever and even the worst stocks stop to take a breather on the way down to zero.

Look for this one to keep rising as people continue to discover all the great things the company has cooking, especially now that they finally have some money to move some of their pipeline along into various other phases and trials.

Some are wondering just how real some of these developments about their H1N1 treatment are.

I think the FDA's vote counts more than all of ours combined and it seems to spell out very clearly: "It's real!"

One article, by the same news portal that's been following this stock all the way up the charts, went out of it's way to tell it's readers that desperate times call for desperate measures in a somewhat long-winded, yet well researched kind of way.

Let me make it as simple as possible.

This is a world wide pandemic. And yes, CNN's Dr. Sanjay Gupta (the same man once in line to be U.S. Surgeon General) who is in a hospital recovering from a bout with the swine flu say it's real too. "This is the sickest I have ever been," he said today.

CEL-SCI knew that when they went to work on this treatment years ago. Forget that it was originally designed to treat something else, their "aha moment" may have come just in time to save us all. Some of the best drug treatments are born that way.

The way we hear it, the FDA may very well issue Emergency Use Authorization (EUA) for this drug candidate. Already they've handed the company something that usually takes years and mountains of paperwork to get. Don't be surprised one bit to see the CDC request and the FDA-issue an Emergency Use Authorization (EUA) letter just like they did for Tamiflu (oseltamivir), Relenza (zanamivir) and a host of other drugs and screening devices no one has ever heard of. That golden ticket, disguised in the form of a letter, will allow either the use of an unapproved medical product or an unapproved use of an approved medical product during certain types of emergencies."


Here it is in it's entirety:

Swine Flu Stocks Moving Markets at Mid Week - news from CBS MoneyWatch.com

[marce]

CVM is headed back to the 1.70's

[ajfavstocks]

I hope this will be trading between $1.80 -$2.10 on monday

[arnie071]

Small Cap H1N1 Biotech Players Mentioned on Bloomberg TV

Small Cap H1N1 Biotech Players Mentioned on Bloomberg TV
Written by Staff and Wire Reports
Friday, 25 September 2009 01:50

Crystal Research Associates’ chief executive officer and cofounder, Jeffrey Kraws, was interviewed by Bloomberg Television on Thursday discussing some of the issues facing biotech companies and their role in the H1N1 flu pandemic.

During the segment, Mr. Kraws noted recent advances that have been made in vaccine and treatment technologies, including those at CEL-SCI Corporation (AMEX:CVN), Generex Biotechnology (NASDAQ:GNBT), and Unilife Medical Solutions Limited (ASX:UNI). Video of the segment appears below.

A doctor at a national, nonprofit consumer healthcare advocacy group which represent public interests in Congress and the executive branch informed ************* that Cel-Sci's treatment was chosen over several others which were either considered or submitted by other companies for Emergency Use Authorization review by the Food and Drug Administration. According to the doctor, one company even proposed the use of a new medical device to treat sick patients infected with H1N1. The device reportedly used some form of light energy to "clean the infected patient's blood, inactivate the virus and boost the immune system." The entire process would only take half an hour and it could be administered in any medical facility or laboratory.

Last week, CEL-SCI announced that the U.S. Food and Drug Administration (FDA) had indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

U.S. Government Officials have reportedly become increasingly concerned about the Swine Flu pandemic since a review of the key indicators by the Centers for Disease Control found that during the last few weeks, influenza activity increased significantly in the United States compared to prior weeks. Visits to doctors for influenza-like illness (ILI) are increasing nationally. Visits to doctors for influenza-like illness are higher than what is expected during this time of year and have increased for five consecutive weeks now. This is very unusual for this time of year.

Twenty-one states are reporting widespread influenza activity and hospitalization rates for adults and children are higher than expected for this time of year.

[jokesola]

thanks. i will keep on my watch list